PL1934388T3 - Sposób projektowania leków - Google Patents

Sposób projektowania leków

Info

Publication number
PL1934388T3
PL1934388T3 PL06790302T PL06790302T PL1934388T3 PL 1934388 T3 PL1934388 T3 PL 1934388T3 PL 06790302 T PL06790302 T PL 06790302T PL 06790302 T PL06790302 T PL 06790302T PL 1934388 T3 PL1934388 T3 PL 1934388T3
Authority
PL
Poland
Prior art keywords
drug design
drug
design
Prior art date
Application number
PL06790302T
Other languages
English (en)
Inventor
Gerald B Tometzki
Wim Meutermans
Johannes Zuegg
Original Assignee
Alchemia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005905465A external-priority patent/AU2005905465A0/en
Application filed by Alchemia Ltd filed Critical Alchemia Ltd
Publication of PL1934388T3 publication Critical patent/PL1934388T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18Acyclic radicals, substituted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/02Monosaccharides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06790302T 2005-10-04 2006-10-03 Sposób projektowania leków PL1934388T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2005905465A AU2005905465A0 (en) 2005-10-04 Method of Drug Design
PCT/AU2006/001431 WO2007038829A1 (en) 2005-10-04 2006-10-03 Method of drug design
EP06790302A EP1934388B1 (en) 2005-10-04 2006-10-03 Method of drug design

Publications (1)

Publication Number Publication Date
PL1934388T3 true PL1934388T3 (pl) 2013-04-30

Family

ID=37905903

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06790302T PL1934388T3 (pl) 2005-10-04 2006-10-03 Sposób projektowania leków

Country Status (9)

Country Link
US (2) US8426345B2 (pl)
EP (1) EP1934388B1 (pl)
JP (1) JP5174672B2 (pl)
CN (2) CN102796147A (pl)
CA (1) CA2619457C (pl)
DK (1) DK1934388T3 (pl)
ES (1) ES2400509T3 (pl)
PL (1) PL1934388T3 (pl)
WO (1) WO2007038829A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102796147A (zh) 2005-10-04 2012-11-28 阿尔卡米亚有限公司 化合物库
JOP20190215A1 (ar) * 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1602995A (en) 1994-01-11 1995-08-01 Affymax Technologies N.V. Methods for the solid phase synthesis of glycoconjugates
JP2000507246A (ja) 1996-03-21 2000-06-13 トランセル テクノロジーズ インク. 固体相のリポグリコペプチドライブラリー、組成物及び方法
DE69835679T2 (de) * 1997-08-28 2007-08-23 Biomira, Inc., Edmonton Zufälligverteilt erzeugte kombinatorische peptidbibliotheken
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
MXPA00012237A (es) * 1998-06-10 2002-11-15 Glycodesign Inc Biblioteca de compuestos combinatorios derigidos y ensayos de alto rendimiento para seleccionar los mismos.
US7338932B2 (en) * 2000-05-11 2008-03-04 Glycozym Aps Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments
AUPS143402A0 (en) 2002-03-28 2002-05-09 Alchemia Pty Ltd Anomeric derivatives of monosaccharides
AU2002950657A0 (en) * 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
EP1732573A4 (en) * 2004-04-08 2010-09-01 Alchemia Ltd BIOLOGICALLY EFFECTIVE COMPOUNDS WITH ANTIANGIOGENIC PROPERTIES
CN102796147A (zh) 2005-10-04 2012-11-28 阿尔卡米亚有限公司 化合物库

Also Published As

Publication number Publication date
WO2007038829A1 (en) 2007-04-12
US20090163373A1 (en) 2009-06-25
EP1934388B1 (en) 2012-12-05
CN101278079B (zh) 2012-09-19
ES2400509T3 (es) 2013-04-10
US20130172210A1 (en) 2013-07-04
DK1934388T3 (da) 2013-02-25
CA2619457A1 (en) 2007-04-12
CN102796147A (zh) 2012-11-28
EP1934388A1 (en) 2008-06-25
EP1934388A4 (en) 2010-07-21
JP5174672B2 (ja) 2013-04-03
US9709571B2 (en) 2017-07-18
US8426345B2 (en) 2013-04-23
JP2009510130A (ja) 2009-03-12
CN101278079A (zh) 2008-10-01
WO2007038829A8 (en) 2008-03-27
CA2619457C (en) 2016-09-06

Similar Documents

Publication Publication Date Title
ZA200805297B (en) Method of using ß-hydroxy-ß-methylbutyrate
GB0526291D0 (en) Therapeutic method
PL1802579T3 (pl) Pochodne 3-aryloaminopirydynowe
IL185757A0 (en) Methods of decreasing calcifcation
EP1855729A4 (en) sterilization
IL196228A0 (en) 4-hydroxythiobenzamide derivatives of drugs
HK1139986A1 (en) Pharmaceutical manufacturing methods
ZA200806318B (en) Drug combinations
IL197883A0 (en) Combination drug
EP1964538A4 (en) PROCESS FOR THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
GB0910201D0 (en) The preparation method of 2-deoxy-l-ribose
ZA200900230B (en) 4-hydroxythiobenzamide derivatives of drugs
EP1871344A4 (en) INHIBITABLE MEDICINAL PRODUCT
EP1879013A4 (en) METHOD FOR CONSTRUCTING SELF-VULGATED DRUG ORMULATIONS
EP1860435A4 (en) PROCESS FOR SIMPLE ANALYSIS OF A MEDICINAL PRODUCT
PL1934388T3 (pl) Sposób projektowania leków
GB0607153D0 (en) Therapeutic Method
GB2443299B (en) Method of monodiameter well construction
TWI372053B (en) Combination drug
TWM292838U (en) Structure of mandril
AU2005905465A0 (en) Method of Drug Design
GB0622332D0 (en) Drug
GB0509930D0 (en) Therapeutic method
GB0521562D0 (en) Therapeutic method
GB0521547D0 (en) Therapeutic method